摘要
Abstract
OBJECTIVE: To investigate the efficacy and safety of rosuvastatin in the treatment of blood-lipoid metabolism disorder in patients with early diabetic nephropathy complicating with hyperlipidemia. METHODS: A total of 104 patients with early diabetic nephropathy complicating with hyperlipidemia were randomly divided into control group (36 cases), rosuvastatin 10 mg·d-1 therapy group (33 cases) and rosuvastatin 20 mg·d-1 therapy group (35 cases). After 6 months treatment, the changes of total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), urinasryalbumin excretion rate (UAER), Scr and high sensitive C-reactive protein (CRP) were compared among 3 groups. RESULTS: After 6 months of rosuvastatin treatment, the levels of TC, TG, LDL-C and CRP of 10 mg·d-1 group and 20 mg·d-1 group decreased significantly while HDL-C increased. The difference was significant (P<0.05). LDL-C level decreased more significantly in 20 mg·d-1 group, but the difference was not significant (P>0.05). UAER and Scr had no significant difference before and after treatment, there was no statistical significance (p>0.05). CONCLUSION: Rosuvastatin 10 mg·d-1 and 20 mg·d-1 can reduce levels of TC, TG, LDL-C, CRP and increase HDL-C in patients with early diabetic nephropathy complicating with hyperlipidemia and reduce hyperlipidemia. They have no adverse effects on renal function.关键词
瑞舒伐他汀/糖尿病肾病/高脂血症/血脂代谢紊乱Key words
Rosuvastatin/Diabetic nephropathy/Hyperlipidemia/Blood-lipoids metabolism disorder分类
医药卫生
